Researchers Identify Potential Brain Cancer Target
Posted on: Monday, 16 January 2006, 15:02 CST
A research team at UT Southwestern Medical Center has discovered a cell-signaling mechanism instrumental in the most common brain cancer in adults. The discovery could lead to the development of therapeutics for the disease.
Therapeutic drugs based on the research would target the epidermal growth factor receptor genes that play a major role in the development of deadly brain tumors, said the researchers, who reported their results in the journal Cancer Research.
The median survival of patients with glioblastoma multiforme (GBM), a cancer of the supportive tissue of the brain, currently is about one year after diagnosis with the best treatments available.
Researchers have known for years that tumor cells proliferate out of control by a mechanism characterized by an abnormally high number of copies of the epidermal growth factor receptor gene (EGFR). This overexpression of EGFR is a striking feature of GBM, present in 40% to 50% of tumors and results in an uncontrolled multiplication of both normal EGFR and a mutant form called EGFRvIII.
While studying human brain tumor tissue and human brain tumor cells from cell lines grown in the laboratory, the researchers discovered that EGFRvIII generates a unique pattern of signaling (distinct from normal EGFR) that causes brain cancer cells in GBM to grow and multiply unchecked.
"The better we understand the signaling mechanisms of the normal and the mutant EGFR, the better we can manipulate or control them," said Dr Amyn Habib, assistant professor of neurology at UT Southwestern and the study's senior author. "Our findings suggest that you have to target both the mutant and the normal EGFR based on the mechanism we described."
Source: Datamonitor
Related Articles
- Advalytix Announces Study of Single Circulating Tumor Cells With the M. D. Anderson Cancer Center
- Study: EGFR Protects Cancer Cells
- Immunicon Corporation Announced the Filing for FDA Clearance of the CellSearch(TM) Circulating Tumor Cell Kit for Monitoring Patients With Metastatic Androgen-Independent Prostate Cancer
- CellSearch(TM) Circulating Tumor Cell Kit Receives FDA Clearance for Monitoring Patients With Metastatic Colorectal Cancer
- Circulating Tumor Cells Help Treatment
- OHSU Cancer Institute Researcher Identifies Protein Marker for Prostate Cancer Survival
- CellSearch(TM) Circulating Tumor Cell Kit Receives FDA Clearance for Monitoring Patients With Metastatic Breast Cancer
- Researchers Increase Cell Death in Tumor Targets
- Missing Protein May Hold Lung Cancer Key -Research
- Immunicon Corporation Announces Presentation of Data on Circulating Tumor Cells in 'Non-Measurable' Metastatic Breast Cancer at the 2005 American Association of Clinical Oncology (ASCO) Annual Meeting
User Comments (0)

RSS Feeds